Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1993;45(4):373-6.
doi: 10.1007/BF00265958.

Pharmacodynamics and pharmacokinetics of eptastigmine in elderly subjects

Affiliations

Pharmacodynamics and pharmacokinetics of eptastigmine in elderly subjects

A Auteri et al. Eur J Clin Pharmacol. 1993.

Abstract

Eptastigmine is a new cholinesterase inhibitor, which may be potentially useful for the symptomatic treatment of Alzheimer's disease. A preliminary evaluation of its pharmacodynamic and pharmacokinetic profiles in the elderly has now been made in 6 healthy subjects (63-84 years of age) given 30 mg eptastigmine as a single oral dose. Blood was collected prior to and 1, 2, 3, 4, 6, 8, and 12 h after eptastigmine administration for measurement of cholinesterase inhibition in plasma and red blood cells and the plasma drug concentrations. The maximum plasma cholinesterase inhibition was 17%, which was reached 2.7 h after treatment. In red cells the maximum inhibition of the enzyme was 29% after 3.8 h. The estimated half-time of cholinesterase recovery was 12.4 h in plasma and 13.6 h in red blood cells. The peak plasma concentration of eptastigmine of 0.86 ng.ml-1 was reached after 1.4 h. Following absorption the drug was rapidly distributed into tissues (t1/2 alpha = 0.44 h) and then eliminated with a half-life of 12.1 h. The drug was well tolerated in all but one subject, who showed bradycardia with hypertension and nausea for about 2 h after the dose. The results indicate that oral administration of eptastigmine to elderly subjects produces long lasting inhibition of cholinesterase activity in plasma and in red blood cells.

PubMed Disclaimer

References

    1. Am J Psychiatry. 1982 Nov;139(11):1421-4 - PubMed
    1. Br Med Bull. 1986 Jan;42(1):63-9 - PubMed
    1. Life Sci. 1988;43(23):1921-8 - PubMed
    1. Eur J Biochem. 1986 May 15;157(1):115-20 - PubMed
    1. N Engl J Med. 1986 Nov 13;315(20):1241-5 - PubMed

Publication types

LinkOut - more resources